Estimating the burden of serious fungal diseases in Canada

concern worldwide. The global burden of these infections in Canada is unknown. In this study, we sought to estimate the national incidence and prevalence of serious fungal diseases in Canada.

[1]  O. Decaux,et al.  Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. , 2014, The American journal of medicine.

[2]  J. Bergeron,et al.  Incidence of invasive aspergillosis following remission-induction chemotherapy for acute leukemia: a retrospective cohort study in a single Canadian tertiary care centre. , 2014, CMAJ open.

[3]  D. Cole,et al.  Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. , 2013, Medical mycology.

[4]  I. Litvinov,et al.  Endemic human blastomycosis in Quebec, Canada, 1988–2011 , 2012, Epidemiology and Infection.

[5]  B. Lebeau,et al.  Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  D. Cole,et al.  Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. , 2011, Bulletin of the World Health Organization.

[7]  B. Yip,et al.  Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study , 2011, AIDS research and therapy.

[8]  M. Arendrup.  Epidemiology of invasive candidiasis , 2010, Current opinion in critical care.

[9]  D. Denning,et al.  Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma , 2010, European Respiratory Journal.

[10]  T. Peláez,et al.  Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  J. Chmiel,et al.  AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study , 2010, AIDS.

[12]  R. Hogg,et al.  Expanding HAART Treatment to All Currently Eligible Individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada , 2010, PloS one.

[13]  E. Anaissie,et al.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Desenclos,et al.  Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006 , 2009, Emerging infectious diseases.

[15]  F. Scheutz,et al.  Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. , 2008, Oral diseases.

[16]  J. Brophy,et al.  Blastomycosis in Ontario, 1994–2003 , 2006, Emerging infectious diseases.

[17]  T. Boekhout,et al.  A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Nicolle,et al.  Invasive fungal infections in Canada from 1992 to 1994. , 1998, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[19]  M. Libman,et al.  Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[20]  E. Smith,et al.  Trends and patterns of opportunistic diseases in Danish AIDS patients 1980-1990. , 1990, Scandinavian journal of infectious diseases.

[21]  Dr. Werner Mendling.  Vulvovaginal Candidosis , 1988, Springer Berlin Heidelberg.